In this issue:
Tofacitinib VTE risk vs TNF inhibitors
Modulation of IL-23 signaling with guselkumab in PsA
Canakinumab for cryopyrin-associated periodic syndrome
Upadacitinib versus methotrexate monotherapy in RA
Tofacitinib vs TNF inhibitors for RA in Latin America
B cell depletion in patients receiving long-term rituximab for RA
Cardiovascular events with JAK inhibitors vs biologic DMARDs
Tocilizumab in polymyalgia rheumatica
Second TNF inhibitor vs non-TNF biologic in JIA
Bimekizumab vs secukinumab and ixekizumab for axial SpA
Please login below to download this issue (PDF)